Oxaliplatin

Malignant Germ Cell Tumor

National Cancer Institute (NCI)Small moleculePhase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

25 Active assets in the Malignant Germ Cell Tumor cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Children's Oncology Group	Phase 3	BB
Etoposide Children's Oncology Group	Phase 3	BB
Nivestim Children's Oncology Group	Phase 2	B
Cis-Diamminedichloroplatinum Ii Children's Oncology Group	Phase 3	B
Bleomycin Children's Oncology Group	Phase 3	B

View all 35 →

Same molecule, other indications

Oxaliplatin is also rated in:

exocrine pancreatic carcinomaActive

BBB

Indicative · Phase 2/3

78 / 100

colon adenocarcinomaActive

BBB

Indicative · Phase 3

77 / 100

colorectal neoplasmActive

BBB

Indicative · Phase 4

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.